Related Experiment Video
Updated: Oct 18, 2025

11:17
A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
Published on: August 11, 2018
12.2K
TSST-1+Staphylococcus aureus in Bullous Pemphigoid
Kelly N Messingham1, Michael P Cahill2, Samuel H Kilgore2
1Department of Dermatology, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA.
The Journal of Investigative Dermatology
|October 4, 2021
Summary
Staphylococcus aureus, particularly toxic shock syndrome toxin-1 positive strains, is prevalent in bullous pemphigoid lesions. Early antibiotic treatment targeting this bacteria may benefit patients and reduce infection risk.
Area of Science:
- Dermatology
- Microbiology
- Immunology
Background:
- Bullous pemphigoid (BP) is an autoimmune blistering disease.
- The role of bacterial infections, specifically Staphylococcus aureus, in BP pathogenesis remains under investigation.
Purpose of the Study:
- To investigate the prevalence and characteristics of Staphylococcus aureus colonization in patients with new-onset bullous pemphigoid.
Main Methods:
- Compared S. aureus colonization rates in BP lesions, patient nares/skin, and healthy controls.
- Analyzed toxin production (toxic shock syndrome toxin-1, enterotoxin gene clusters) of lesional S. aureus isolates.
- Assessed the impact of antibiotics on S. aureus colonization and clinical outcomes.
Main Results:
- S. aureus colonization was significantly higher (3-6 fold) in BP lesions compared to patient skin/nares and controls.
- 96% of lesional isolates produced toxic shock syndrome toxin-1; many also expressed enterotoxin gene clusters.
- Antibiotic treatment targeting S. aureus led to bacterial elimination and clinical improvement in BP patients.
Conclusions:
- Toxic shock syndrome toxin-1 positive S. aureus is frequently found in bullous pemphigoid lesions.
- Early antibiotic intervention may be beneficial for BP patients by reducing S. aureus colonization.
- S. aureus colonization may act as an infection source in BP, especially in immunosuppressed individuals.

